Trials / Recruiting
RecruitingNCT06406634
Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Hunan Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the effectiveness of Cadonilimab(AK104) in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cadonilimab | Injectable solution |
| DRUG | Lenvatinib | capsule |
Timeline
- Start date
- 2024-05-15
- Primary completion
- 2026-04-20
- Completion
- 2027-04-20
- First posted
- 2024-05-09
- Last updated
- 2024-05-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06406634. Inclusion in this directory is not an endorsement.